Donor and recipient characteristics
Study no. . | Disease . | Age of recipient at alloSCT, y . | Hemopoietic stem cell source . | GVHD, acute/chronic . | Donor/recipient sex . | Donor/recipient HCMV serology* . | Donor/recipient EBV serology* . | HCMV DNAemia or HCMV disease† . | Immunosuppression‡and clinical outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 01 | AML | 47 | Sibling PBSC | Nil/limited | M/M | +/+ | ND | Nil | CSA 1-12 mo, PD 13-15 mo |
| 02 | B-ALL | 23 | Sibling PBSC | II/nil | M/F | +/+ | —/+ | Nil | CSA 0-3 mo |
| 03 | CML | 38 | Sibling PBSC | Nil/extensive | F/M | +/+ | ND | Nil | CSA 0-10 mo, PD 10-15 mo, AZ 10-35 mo |
| 04 | CML | 47 | Sibling BM | III/nil | M.M | +/+ | ND | Nil | CAS 0-12 mo |
| 05 | CML | 45 | TCD-MUD BM | Nil/limited | M/M | —/+ | ND | HCMV retinitis 5 mo‡ | CSA 0-20 mo, PD 9-11 mo |
| 06 | CML | 39 | Sibling BM | Nil/nil | F/F | +/— | —/+ | Nil | CSA 0-6 mo |
| 07 | RAEB-T | 39 | Sibling PBSC | Nil/limited | F/F | +/— | +/+ | Nil | Still on CSA at 30 mo, PD 7-13 mo, AZ 11-19 mo |
| 08 | RAEB-T | 41 | Sibling PBSC | IV/extensive | M/M | +/— | ND | Nil | CSA 0-4 mo,§ died at 6 mo |
| 09 | AML | 46 | Sibling PBSC | III/limited | M/F | +/— | +/+ | Nil | CSA 0-4 mo and 12-21 mo. PD 4-6 mo |
| 10 | CML | 19 | TCD-MUD BM | I/nil | M/F | +/+ | ND | HCMV DNAemia at 1 mo and 4 mo‡ | CSA 0-4 mo, died at 6 mo |
Study no. . | Disease . | Age of recipient at alloSCT, y . | Hemopoietic stem cell source . | GVHD, acute/chronic . | Donor/recipient sex . | Donor/recipient HCMV serology* . | Donor/recipient EBV serology* . | HCMV DNAemia or HCMV disease† . | Immunosuppression‡and clinical outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 01 | AML | 47 | Sibling PBSC | Nil/limited | M/M | +/+ | ND | Nil | CSA 1-12 mo, PD 13-15 mo |
| 02 | B-ALL | 23 | Sibling PBSC | II/nil | M/F | +/+ | —/+ | Nil | CSA 0-3 mo |
| 03 | CML | 38 | Sibling PBSC | Nil/extensive | F/M | +/+ | ND | Nil | CSA 0-10 mo, PD 10-15 mo, AZ 10-35 mo |
| 04 | CML | 47 | Sibling BM | III/nil | M.M | +/+ | ND | Nil | CAS 0-12 mo |
| 05 | CML | 45 | TCD-MUD BM | Nil/limited | M/M | —/+ | ND | HCMV retinitis 5 mo‡ | CSA 0-20 mo, PD 9-11 mo |
| 06 | CML | 39 | Sibling BM | Nil/nil | F/F | +/— | —/+ | Nil | CSA 0-6 mo |
| 07 | RAEB-T | 39 | Sibling PBSC | Nil/limited | F/F | +/— | +/+ | Nil | Still on CSA at 30 mo, PD 7-13 mo, AZ 11-19 mo |
| 08 | RAEB-T | 41 | Sibling PBSC | IV/extensive | M/M | +/— | ND | Nil | CSA 0-4 mo,§ died at 6 mo |
| 09 | AML | 46 | Sibling PBSC | III/limited | M/F | +/— | +/+ | Nil | CSA 0-4 mo and 12-21 mo. PD 4-6 mo |
| 10 | CML | 19 | TCD-MUD BM | I/nil | M/F | +/+ | ND | HCMV DNAemia at 1 mo and 4 mo‡ | CSA 0-4 mo, died at 6 mo |
AML indicates acute myeloid leukemia; PBSC, peripheral blood stem cell; ND, not done; CSA, cyclosporin A; PD, prednisolone; B-ALL, B-acute lymphoblastic leukemia; CML, chronic myeloid leukemia; AZ, azathioprine; BM, bone marrow; TCD-MUD, T-cell-depleted matched-unrelated donor; RAEB-T, refractory anemia with excess blasts in transformation.
Recipient serology performed on a sample taken before transplantation.
HCMV DNAemia was monitored by weekly plasma samples tested by PCR, until cessation of immunosuppression.
All episodes of HCMV infection resolved with ganciclovir treatment.
Patient was treated palliatively from 4 months onward.